Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients (VANCS II)
Sponsor: Instituto do Cancer do Estado de São Paulo
This PHASE3 trial investigates Septic Shock and is currently completed. Instituto do Cancer do Estado de São Paulo leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jun 2017 — Dec 2017 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto do Cancer do Estado de São Paulo
For direct contact, visit the study record on ClinicalTrials.gov .